Navigation Links
Microbix Sales Grow Over 30% In The Second Quarter; Up 43% In The First Half '09
Date:5/14/2009

March 31 March 31 -------- -------- 2009 2008 2009 2008 ---- ---- ---- ---- $ $ $ $ Sales 1,570,204 1,179,771 3,176,728 2,216,622 Net Profit (loss) (512,834) (1,337,698) (1,096,502) (2,282,685) Net Profit (loss) per share (0.01) (0.02) (0.01) (0.05) Cash Flow (244,708) (1,771,934) (2,856,777) 3,831,239

Microbix specializes in the development of biological technologies and commercializing them through global partners. The Company has intellectual property in large market biotherapeutic drugs, vaccine technologies and animal reproduction technologies. Established in 1988, Microbix is headquartered in Toronto.

This press release contains forward-looking statements, which are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements including the risks associated with failure to get authorization to release Kinlytic for distribution in the US from the FDA, inability to complete financing for the Hunan China project currently the subject of financing; risks associated with commercializing the technologies; risks associated with failure to develop and commercialize SST; non-adoption of SST. These forward-looking statements represent the Company's judgment as of the date of this press release. The Company disclaims any intent or obligation to update these forward-looking statements.


'/>"/>
SOURCE Microbix Biosystems Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. ImaRx Therapeutics Signs Letter of Intent With Microbix Biosystems for the Sale of Urokinase
2. Microbix Uses Core Business Cashflow To Fund Late-Stage Pipeline To Build Shareholder Value In 2009
3. Microbix First Quarter Sales Grow Over 50% With Continued Progress On The Pipeline
4. Microbix Announces A New Technology Platform For The SST Project
5. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
6. Pathway Medical Technologies Adds Joe Rafferty as VP, Sales, and Moves To Larger Facility to Accommodate Rapid Growth
7. International Isotopes Inc. Announces Completion of an Exclusive Distributor Agreement for Sales of New Style Transportation Containers
8. Kline Study: Better Brushing Habits Boost European Oral Care Sales
9. BioElectronics Corporation Announces Singapore and Malaysia Sales
10. Thermo Fisher Scientific Acquires Instrument Sales Business of Davis Inotek
11. AMDLs Jade Pharmaceutical Subsidiary Announces New Product Strategy; Six New Products, Including One With Sales Projected at Upwards of $10 Million, Under Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)... 2015  Pfenex Inc. (NYSE MKT: PFNX) a clinical-stage ... including high value and difficult to manufacture proteins, today ... 6,000,000 shares of its common stock at a price ... shares being offered, 2,610,000 are being offered by Pfenex ... existing stockholders. Pfenex will not receive any proceeds from ...
(Date:4/24/2015)... 2015 Seoul Semiconductor announced the ... applications in the lighting market. In recent ... this technology in emerging markets such as Russia, ... range of applications such as streetlight and area ... , First launched in 2005 the Acrich technology ...
(Date:4/23/2015)... 2015 /CNW/ - A new and innovative service has ... North America,s largest packaging trade ... in the "Sustainability, service" category of the PAC ... Comparison" is a service that scores clients, packaging ... peers. This benchmarking process shows clients how their ...
(Date:4/23/2015)... WuXi PharmaTech (Cayman) Inc. (NYSE: WX ), a ... the pharmaceutical, biotechnology and medical device industries, with operations ... the United States , today announced that it ... 2015 after the New York Stock Exchange closes on ... May 14, 2015 Shanghai time). The earnings release will ...
Breaking Biology Technology:Pfenex Inc. Announces Pricing Of Follow-on Offering 2Acrich Technology from Seoul Semiconductor Adopted in Installations Worldwide 2WuXi PharmaTech Schedules First-Quarter 2015 Earnings Release 2WuXi PharmaTech Schedules First-Quarter 2015 Earnings Release 3
... China, Sept. 22 /PRNewswire-Asia-FirstCall/ -- China Pharma Holdings, ... ), which develops, manufactures, and markets specialty pharmaceutical ... has successfully completed Phase I clinical trials of ... Cephalosporin continues to be the most widely prescribed ...
... Advanced Cell Technology, Inc. ("ACT"; OTC Bulletin Board: ... Scientific Officer, Robert Lanza, MD, and Kwang-Soo Kim, PhD, ... National Institutes of Health (NIH) Director,s Opportunity Award for ... Better Treatments" under the American Recovery & Reinvestment Act ...
... Medicago Inc. (TSX: MDG), a biotechnology company focused ... on proprietary manufacturing technologies and Virus-Like Particles (VLPs), ... applications under the Patent Cooperation Treaty (PCT) that ... proteins and VLPs. "The extraction and ...
Cached Biology Technology:China Pharma Holdings, Inc. Successfully Completes Phase I Clinical Trials of New Anti-Drug-Resistance Antibiotic 2China Pharma Holdings, Inc. Successfully Completes Phase I Clinical Trials of New Anti-Drug-Resistance Antibiotic 3China Pharma Holdings, Inc. Successfully Completes Phase I Clinical Trials of New Anti-Drug-Resistance Antibiotic 4Drs. Robert Lanza and Kwang-Soo Kim Win Prestigious NIH Director's Award 2Drs. Robert Lanza and Kwang-Soo Kim Win Prestigious NIH Director's Award 3Medicago discovers breakthrough method of preparing plant derived recombinant proteins and VLPs and files two PCT patent applications 2Medicago discovers breakthrough method of preparing plant derived recombinant proteins and VLPs and files two PCT patent applications 3
(Date:4/20/2015)... , April 20, 2015 Huntington Memorial ... Valley to implant a new miniaturized, wireless monitoring sensor ... is the first and only FDA-approved heart failure monitoring ... admissions when used by physicians to manage heart failure. ... that is implanted in the pulmonary artery (PA) during ...
(Date:4/14/2015)...  HYPR Corp. today announced it has joined ... tm , an industry consortium transforming online authentication ... technology and collaborate to deliver open specifications for ... and private, and easier to use. ... sensitive user information and eliminates the dependency on ...
(Date:4/13/2015)... CHICAGO , April 13, 2015  higi, a ... with ways to more fully engage with their communities ... its industry-leading, privacy protected and secure API.  ... API enables the most accessible, affordable, and convenient vehicle ... The API will ...
Breaking Biology News(10 mins):Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3
... Purdue University biochemist has demonstrated a process using nanotechnology ... which may help reduce drug side effects. W. ... developed a nanopolymer that can be coated with drugs, ... in the cells the drug has entered. Since they,re ...
... WEST LAFAYETTE, Ind. - Chemical changes in tree leaves ... climate change may reduce the availability of soil nutrients, ... an associate professor of forestry and natural resources, found ... tannin when exposed to hot, droughtlike conditions. Those tannins, ...
... an eco-friendly diesel fuel have more red lights in their ... completely green would not only bend the laws of physics, ... limited, and since we can,t use more than what Earth ... sources like algae," said Peter Pfromm, professor of chemical engineering ...
Cached Biology News:Nanopolymer shows promise for helping reduce cancer side effects 2Drought-exposed leaves adversely affect soil nutrients, study shows 2Economics, physics are roadblocks for mass-scale algae biodiesel production, study finds 2Economics, physics are roadblocks for mass-scale algae biodiesel production, study finds 3Economics, physics are roadblocks for mass-scale algae biodiesel production, study finds 4
POU domain, class 2, transcription factor 2,...
... HEK 293T cell line contains the b-lactamase ... response element (CRE). To obtain the cell ... HEK 293T cells by lentivirus. Subsequent flow ... to forskolin stimulation (Figure 1). The CellSensor ...
activating transcription factor 4 (tax-responsive enhancer element B67),...
Reactivity: Human...
Biology Products: